Phase 1/2 Clinical Trial Underway Fibrocell has initiated a Phase 1/2 clinical trial of FCX-007 for the treatment of RDEB. The primary objective of this open-label clinical trial is to evaluate the safety of FCX-007 in RDEB patients. Additionally, the trial will assess the mechanism of action of FCX-007 through the evaluation of COL7 and…